Prothena Presents Pipeline Update Highlighting Two Partnered Phase 3 Programs

Bitget2026/11/05 22:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prothena achieved a $50 million Phase 3 enrollment milestone for coramitug, its partnered ATTR cardiomyopathy treatment.
Remaining potential milestones exceed $2.25 billion across three partnered programs, with sales royalties also available from prasinezumab and moponetug.
Moponetug Phase 2 TargetTau-1 data in Alzheimer's disease are expected in the first half of 2027.
Phase 3 trials of prasinezumab for Parkinson's disease and coramitug for ATTR cardiomyopathy are expected to finish in 2029.
Research investment focuses on preclinical CYTOPE technology and PRX012-TfR, with additional collaborations and licensing deals being explored for unpartnered programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prothena Presents Pipeline Update Highlighting Two Partnered Phase 3 Programs

You may also like

Crypto prices